



(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/33 (2006.01)
A61K 31/495 (2006.01) A61P 5/08 (2006.01)
A61K 31/496 (2006.01)

(21) International Application Number:

PCT/US2024/029588

(22) International Filing Date:

16 May 2024 (16.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/503,248 19 May 2023 (19.05.2023) US
63/631,658 09 April 2024 (09.04.2024) US

(71) Applicant: **CRINETICS PHARMACEUTICALS, INC.**
[US/US]; 6055 Lusk Blvd., San Diego, California 92121 (US).

(72) Inventors: **AYALA, Alejandro**; c/o Crinetics Pharmaceuticals, Inc., 6055 Lusk Blvd., San Diego, California 92121 (US). **KRASNER, Alan**; c/o Crinetics Pharmaceuticals, Inc., 6055 Lusk Blvd., San Diego, California 92121 (US). **LUO, Sha**; c/o Crinetics Pharmaceuticals, Inc., 6055 Lusk


Blvd., San Diego, California 92121 (US). **TRAINER, Peter**; c/o Crinetics Pharmaceuticals, Inc., 6055 Lusk Blvd., San Diego, California 92121 (US).

(74) Agent: **CAPPS, Kevin** et al.; c/o Crinetics Pharmaceuticals, Inc., Legal IP, 6055 Lusk Blvd., San Diego, California 92121 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA



EDC: 04MAR2024, Lab: 04Mar2024

FIG. 1

(57) Abstract: Provided are compositions and methods for the treatment of congenital adrenal hyperplasia (CAH).

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*